New York University

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut Curie

Universitè De Montpellier

Inserm

Nicolas Manel

Dan R Littman

Matteo Gentili

Marc Sitbon

Jean-Luc Battini

Naomi Taylor

Felix Jinhyun Kim

Matthieu Piel

Sandrina Kinet

Jonathan Maelfait

Satoh Takeshi

Jan Rehwinkel

Anne Bridgeman

Matthew Raab

Tamara Davenne

Takeshi Satoh

The present invention provides an in vitro method for monitoring interphase nuclear envelope rupture events in a eukaryotic cell or screening or identifying compound capable of increasing or decreasing the intensity and/or frequency of interphase nuclear envelope rupture events in a eukaryotic cell. These methods relate on a protein having a cytosolic non-nuclear localization in interphase and a non-sequence specific DNA binding activity. Interphase nuclear envelope rupture events are characterized by the presence of the protein of the invention in the nucleus of the eukaryotic cell.

Method to monitor and quantify interphase nuclear envelope rupture events

The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides.

Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response

The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.

GLUT-1 as a receptor for HTLV envelopes and its uses

The present invention is directed to an in vitro method for promoting differentiation and proliferation of human T helper lymphocytes that express IL17 (Th-IL17+ cells). The instant method may be used to generate a population of human T helper lymphocytes that express IL17 (Th-IL17+ cells) in vitro. Methods for screening to identify agents capable of modulating Th-IL17+ cell differentiation are also encompassed by the present invention. Isolated, pure populations of homogeneous Th-IL17+ cells that do not express cellular markers characteristic of Th1, Th2, or Treg cells are also encompassed herein.

Methods for in vitro differentiation of TH-17+ cells

The present invention relates to enhancing, modulating or stimulating the innate immune response to HIV-1 and other viral pathogens and to the modulation and application of immune modulators and peptides for HIV-1 or other pathogen vaccines. The invention provides methods and means to activate an innate response to HIV-1 utilizing or via the HIV capsid protein or peptide, including modulating the binding of cyclophilin A to HIV capsid protein and modulating the ability of HIV to activate the major innate transcription factor IRF3 and interferon. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating innate immune response, particularly to HIV-1.

Methods, agents and peptides for inducing an innate immune response in HIV vaccination

Methods for in vitro differentiation of Th-17+ cells

Methods for in vitro differentiation of Th-17+cells

Growing community of inventors

Paris, France

Nicolas Manel